Regulators Turn Their Attention to AI Governance as Biotech Oversight Tightens for 2026
Biotechnology regulators are entering 2026 with a markedly different posture than in prior years, one defined less by narrow rule enforcement and more by scrutiny of how companies design, govern, and explain their operational systems. According to recent analysis by Outside General Counsel, this shift is especially pronounced for biotech companies that have embedded artificial intelligence into research, clinical development, and quality systems, where regulators are increasingly focused on process integrity rather than just end results.
Featured News
Argentina’s Tavarone Strengthens Competition Team With Partner Promotion
Nov 22, 2026 by
CPI
CFTC Loses Emergency Bid to Block New York Enforcement Against Kalshi
Nov 22, 2026 by
CPI
Dollar General Faces Expanding FTC Lawsuit as 10 More States Join
Nov 22, 2026 by
CPI
Nvidia Faces SEC Probe Into Potential Accounting Issues
Nov 22, 2026 by
CPI
Senators Move to Strip Major League Baseball of Century-Old Antitrust Protection
Nov 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff